Harvard Bioscience Q2 Adj EPS $0.04 Misses $0.05 Estimate, Sales $28.80M Miss $29.50M Estimate
Portfolio Pulse from Benzinga Newsdesk
Harvard Bioscience (NASDAQ:HBIO) reported Q2 adjusted earnings of $0.04 per share, missing the analyst consensus estimate of $0.05 by 20%. The company also reported quarterly sales of $28.80 million, missing the analyst consensus estimate of $29.50 million by 2.37%. This represents a decrease in both earnings and sales compared to the same period last year.
August 08, 2023 | 11:20 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Harvard Bioscience's Q2 earnings and sales missed analyst estimates, indicating a potential negative impact on the company's stock price in the short term.
Harvard Bioscience's Q2 earnings and sales fell short of analyst estimates, which could lead to a decrease in investor confidence and a potential drop in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100